Continued concerns over potential regulatory delays for Savient Pharmaceuticals Inc.'s gout drug candidate sent shares lower Tuesday. The stock shed 53 cents, or 12.7 percent, to reach $3.65 in afternoon trading. Shares have traded between $2.80 and $28.42 over the last 52 weeks.
